Clear Search sequence regions


  • adult (5)
  • antibodies (3)
  • asthma (2)
  • biologics (2)
  • child (1)
  • children (1)
  • eosinophilia (1)
  • food (3)
  • granulomatosis (2)
  • humans (1)
  • IL 5 (11)
  • medicines (2)
  • mepolizumab (7)
  • nasal polyps (1)
  • patients (6)
  • phase (1)
  • receptor (1)
  • reslizumab (4)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophilic-associated conditions, particularly in patients with respiratory involvement. Mepolizumab (IL-5 antagonist monoclonal antibody), benralizumab (IL-5 receptor blocker monoclonal antibody), and reslizumab (IL-5 antagonist monoclonal antibody) have collectively contributed to the overall improvement of the disease burden in various conditions. Eosinophilic asthma currently boasts the most robust evidence across all age groups: all three biologics are approved for adults (aged ≥18 years); mepolizumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also in children (aged ≥ 6 years), while bernalizumab was recently approved by the FDA for patients aged ≥6 years in the USA. In chronic rhinosinusitis with nasal polyps, subcutaneous mepolizumab is the only anti-IL-5 therapy approved so far and can be used in adult patients (aged ≥18 years). For eosinophilic esophagitis, conflicting evidence surrounds both mepolizumab, reslizumab, and benralizumab, leading to non-approval of these agents by the FDA/EMA. Recently, mepolizumab was approved for eosinophilic granulomatosis with polyangiitis patients aged ≥6 years or older and for hypereosinophilic syndrome adult patients. A phase III trial proving noninferiority of benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis has been recently published, while evidence on reslizumab is scant. Overall, current evidence on anti-IL-5 biologics for eosinophilic-associated disorders is mostly focused on adults, whereas data for individuals aged under 18 years and over 65 years are scarce, resulting in a lack of evidence, particularly regarding efficacy, for the use of anti-IL-5 agents in these specific patient populations. This review addresses high-quality evidence from randomized controlled trials and real-world post-marketing studies regarding the use of anti-IL-5 therapies for eosinophilic-associated disorders across all age groups, spanning childhood, adulthood, and older age. © 2024. The Author(s).

    Citation

    Carlo Lombardi, Pasquale Comberiati, Erminia Ridolo, Marcello Cottini, Mona Rita Yacoub, Silvia Casagrande, Matteo Riccò, Marco Bottazzoli, Alvise Berti. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. Drugs. 2024 Jun;84(6):661-684

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38849701

    View Full Text